Top Tweets for #IVOSIDENIB
💡 In this interview from #ASCO26, Dr. Sunyoung Lee, of @UTMDAnderson, discusses his retrospective analysis investigating the response to #ivosidenib — an FDA-approved IDH1 inhibitor — in patients with IDH1-mutated #cholangiocarcinoma: https://t.co/Xc68ncq776
Our data from @Hospital_FJD + @hospitalclinic presented at @myESMO #ESMOAsia25
Tumour Grouth Rate (#TGR) can identify anti-tumour effect with cytostatic agents where main response is SD by RECIST
👉 Example: #ivosidenib in #BiliaryMalignancies
@MacarullaTeresa @D_Fernandez_R
キアゲン、日本セルヴィエ株式会社の新規がん治療薬に対するコンパニオン診断薬の保険適用を取得 https://t.co/twxKyahzb5
ちょっとかかりましたけれども, IDH1遺伝子変異陽性のAML（5-10%）に対するTibsovo+Aza（IVO/AZA）治療開始ですね。
#ivosidenib
Memo
FDAは, 再発又は難治性のIDH-1遺伝子変異陽性の骨髄異形成症候群に対するTibsovo (#ivosidenib) を承認（CoDxあり）.
https://t.co/dtBon0arYt
Check out the @FDAOncology Approval Summary: #Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory #MDS with an IDH1 Mut https://t.co/eFKlB8SiO6
Preliminary #efficacy results from #ProvIDHe with #Ivosidenib in #mIDH1 #BiliaryMalignancies presented by #ProfBridgewater at @myESMO #ESMOGI25
Replicated activity (mPFS 4.7 months, ORR 5.7%) 🥳
mOS - 15.5 months (long 😏) - subsequent ttos?
Safety not an issue
#ESMOAmbassadors
Preliminary efficacy results of the phase 3b ProvIDHe study of #ivosidenib in patients with #IDH1- mutated cholangiocarcinoma #CCA at #ESMOGI25 @myESMO #ESMOAmbassadors
[AGILE trial (NCT03173248)]
P: ineligible for intensive chemo, IDH1+AML
E: #Ivosidenib+Aza 72pts
C: Plbo+Aza 74pts
O: F/Umed 12.4mo
EFS [95%CI] 0.33[0.16-0.69]
OS (med) E: 24.0mo vs C: 7.9mo
AE: neutropenia, bleeding
[NEJM 2022; 386: 1519-31]
https://t.co/GvQmOOt32k
🩸ティブソボ錠250㎎（#Ivosidenib）
【効能・効果】#IDH1 遺伝子変異陽性AML（＊CoDX+）
【用法・用量】Azaとの併用において、通常、成人にはイボシデニブとして1日1回500㎎を経口投与する
【重大な副作用】分化症候群・QT延長等
Escucha este resumen con todo lo que debes saber del #Ivosidenib para el tratamiento del #colangiocarcinoma con mutacion #IDH1
Gracias @cofiadeva por tu tiempo!
😊😊
🔊 ¡Nuevo episodio de la 2.ª Ed. de #TooMoreGI! 📷🎙️
La Dra. @DrAngelaLamarca y el Dr. @cofiadeva presentan:
#CáncerVíasBiliares | 🧬 Ivosidenib: un antes y un después en el tratamiento del colangiocarcinoma intrahepático
🎧 Escúchalo aquí 👉: https://t.co/RYJWVH50jG
#Oncología #MedicinaDePrecisión #IDH1 #Investigación
🚨📰🚨
Fantásticas noticias 😊
#ivosidenib financiado en España para pacientes diagnosticados de #colangiocarcinoma con mutación de IDH1
Por fin!! 🥳🥳🥳🥳🥳🥳
@atuvibi @enscca @GrupoTTD @_SEOM
🚨📰🚨
Fantastic news for 🇪🇸
#ivosidenib funded for IDH1 mutant #CCA
Finally!! 🥳🥳🥳🥳🥳🥳
Lots of #BiliaryMalignancy patients were waiting for this!
@atuvibi @enscca @GrupoTTD @_SEOM
This study presents the largest cohort of #IDHMutant #glioma patients treated with an IDH inhibitor (#ivosidenib) outside the context of clinical trials, with 74 patients with newly diagnosed and progressive disease and spans all #tumor grades.
https://t.co/2Vgg94CjfR
#MO138 in #BiliaryCancer at @myesmo #ESMOAsia24 by @LorenzaRimassa
ProvIDHe: phIIIb - Ivosidenib – mIDH1 (iCCA)
Awaited safety/activity – heavily pretreated (>ClarIDHy)
SOC NGS for IDH 👌 (=ClaIDHy (central))
🙏ProvIDHE - 45 Spanish pts could access #Ivosidenib! Funding?
#Ivosidenib in r/r #MDS with #IDH1m
⭐️ 38.9% CR+PR
⭐️ 83.3% ORR
⭐️ mOS 35.7m
⭐️ 10.5% DS 👀
@BloodAdvances
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome https://t.co/X0J9ZoQTyo
On #Heme Today from #EHA2024,
final results from the phase II #IDIOME trial-
Oral #ivosidenib shows promise against IDH1-mutated #myelodysplasticsyndromes in elderly frail pts
#MDS
https://t.co/cJ43TseFHn
#CCA #IDH #ivosidenib #livertwitter #MedEd
🎀Review of IDH mutations and potential therapies for intrahepatic cholangiocarcinoma
✍️IDH1 molecular pathway
✍️Treatment of IDH-mutated CCA
🖇️More: https://t.co/qw0dCa5pvN
The FDA approved #ivosidenib for the treatment of #relapsed or refractory #myelodysplastic syndromes (#MDS) in adults with a susceptible IDH1 mutation. https://t.co/gsL0cuHbff
Summary of 10 new indications/approvals in Heme Malignancies (excluding CART) by @FDAOncology in 2023:
1. #Zanubrutinib
2. #Pirtobrutinib
3. #Polatuzumab
4. #Epcortimab
5. #Glofitamab
6. #Quizartinib
7. #Talquetamab
8. #Elranatamab
9. #Ivosidenib
#HemeTwitter #Oncology
Summary of 10 new indications/approvals in Heme Malignancies (excluding CART) by @FDAOncology in 2023:
1. #Zanubrutinib
2. #Pirtobrutinib
3. #Polatuzumab
4. #Epcortimab
5. #Glofitamab
6. #Quizartinib
7. #Talquetamab
8. #Elranatamab
9. #Ivosidenib
#HemeTwitter #MedTwitter #OncTwitter #mmsm #lymsm
Summary of 10 new indications/approvals in Heme Malignancies (excluding CART) by @FDAOncology in 2023:
1. #Zanubrutinib
2. #Pirtobrutinib
3. #Polatuzumab
4. #Epcortimab
5. #Glofitamab
6. #Quizartinib
7. #Talquetamab
8. #Elranatamab
9. #Ivosidenib
#HemeTwitter #MedTwitter #OncTwitter #mmsm #lymsm
Last Seen Hashtags on Sotwe
밟은빵
Seen from Korea
candid (******************************) filter:videos
minichat
Seen from Turkey
Tajas
Seen from United States
Books
Seen from United Kingdom
เย็ดป้า
Seen from Thailand
伪娘
Seen from United States
vishnupriyabhimaneni
Seen from India
โพธาราม
Seen from Thailand
DobleBlowjob
Seen from Saudi Arabia
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.6M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90.1M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.5M followers
Bill Gates
@billgates
65.3M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers